垂体受体 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
=== Cystic fibrosis === Cystic fibrosis (CF) was first added to newborn screening programs in New Zealand and regions of Australia in 1981, by measuring immunoreactive trypsinogen (IRT) in dried blood spots. After the CFTR gene was identified, Australia introduced a two tier testing program to reduce the number of false positives. Samples with an elevated IRT value were then analyzed with molecular methods to identify the presence of disease causing mutations before being reported back to parents and health care providers. CF is included in the core panel of conditions recommended for inclusion in all 50 states, Texas was the last state to implement their screening program for CF in 2010. Alberta was the first Canadian province to implement CF screening in 2007. Quebec, New Brunswick, Nova Scotia, Newfoundland and Prince Edward Island do not include CF in their screening programs. The United Kingdom as well as many European Union countries screen for CF as well. Switzerland is one of the latest countries to add CF to their newborn screening menu, doing so in January 2011.
Eplerenone is a newer drug that was developed as a spironolactone analog with reduced adverse effects. In addition to the y-lactone ring and the substituent on C-7, eplerenone has a 9α,11α-epoxy group. This group is believed to be the reason why eplerenone has a 20-40-fold lower affinity for the mineralocorticoid receptor than spironolactone. Despite the nonsteroidal nature of finerenone which yields a different lipophilicity and polarity profile for this compound, finerenone's affinity toward mineralocorticoid receptors is equal to that of spironolactone and 500 times that of eplerenone, hinting that the steroidal core component of most antimineralocorticoids is not essential for mineralocorticoid receptor affinity.
Parliament passes the Electoral Amendment Act 2025, which tightens the timeframe for voter registration, bans prisoners from voting, and allows larger anonymous political donations. 17 December: Assistant Commissioner Mike Pannett is appointed as Deputy Police Commissioner. The New Zealand Government agrees to return 3,068 hectares in the upper South Island, including the Kaiteriteri Recreation Reserve and the Abel Tasman Coast Track, plus a $420 million compensation, to Te Tau Ihu Māori as part of the Nelson Tenths settlement. Former Deputy Police Commissioner Jevon McSkimming is sentenced to nine months of home detention after pleading guilty to charges of possessing objectionable material. Primary school teachers affiliated with the New Zealand Educational Institute reject the Government's pay off of a 4.6% pay rise over the next two years. Justice Michele Wilkinson-Smith of the Wellington High Court rules in favour of PATHA's bid to delay an incoming ban on new puberty blocker prescriptions expected to come into effect on 19 December, pending a judicial review. Justice Pheroze Jagose of the Auckland High Court dismisses food processing company Talley's Group's defamation case against broadcaster TVNZ and journalist Thomas Mead over a 2021 story covering its Ashburton plant. One new case of measles is reported in Queenstown, bringing the total number of cases nationwide to 32. Four cases were active at the time.
Prosopagnosia A neurological disorder characterized by the inability to recognize faces, often due to damage in the fusiform face area. Purkinje cell A large, GABAergic neuron located in the cerebellar cortex. It has extensive dendritic branching and is essential for motor coordination. Pyramidal cell A type of excitatory neuron found in the cerebral cortex, especially the motor cortex. Named for its pyramid-shaped soma. Pyramidal tract A major motor pathway that transmits signals from the cerebral cortex to the spinal cord, enabling voluntary movement.
Sources: en.wikipedia.org
== Contraindications == Contraindications of anastrozole include hypersensitivity to anastrozole or any other component of anastrozole formulations, pregnancy, and breastfeeding. Hypersensitivity reactions to anastrozole including anaphylaxis, angioedema, and urticaria have been observed.
=== Recombinant preparations === Follitropin alfa Generic Follitropin alfa injection Brands Gonal-f Cinnal-f Fertilex Ovaleap Bemfola Generic Follitropin alfa / lutropin alfa combination Brands Pergoveris Follitropin beta Generic follitropin beta injection Brands Follistim AQ Puregon Follitropin delta Generic follitropin delta injection Brands Rekovelle The package insert for Gonal-f states that based on physio-chemical tests and bioassays that follitropin beta and follitropin alfa are indistinguishable. Two studies showed no difference. However, a more recent study showed there may be a slight clinical difference, with the alfa form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels. The package insert for Puregon states that structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (hFSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural hFSH. However, these small differences do not affect the bioactivity compared to natural hFSH. Gonal-f was approved for medical use in the European Union in October 1995. Puregon was approved for medical use in the European Union in February 1996. Rekovelle was approved for medical use in the European Union in December 2016.
histone modification The post-translational modification of histone proteins by the chemical attachment of various molecules or functional groups to specific amino acid residues. Because histones form the core of nucleosomes, the modification of exposed parts of their polypeptide chains is used to regulate gene expression by marking them with molecular labels that signal the recruitment of other proteins to induce conformational changes that variously widen or condense the spacing of nucleosomes along strands of DNA, thereby changing the accessibility of nearby DNA sequences to transcriptional machinery. Histones are modified by many different labels, most commonly methylation, acetylation, ubiquitination, phosphorylation, and citrullination.
After the resignations of Kissinger's aides, Nixon took away the authority to tap phones, which he had given Kissinger in May 1969, and gave it to the attorney general, John Mitchell. Unknown to Kissinger, Mitchell had been illegally tapping his phone since the fall of 1969. Adding to the tension, on 2 May 1970, U.S. aircraft bombed North Vietnam for the first time since 1968, causing Senator Fulbright to say, "Good God", when he heard the news. Senate Majority Leader Mike Mansfield said he had trouble believing that Nixon and Kissinger were so reckless. To Nixon, Kissinger accused Laird and/or Rogers of leaking the news of the bombing raid on North Vietnam and asked for the FBI to tap their phones. Without informing Nixon, on 4 May 1970, Laird announced the end of the bombing raids on North Vietnam. On the night of 8 May 1970, Nixon, who had been rattled by the protests, stayed up all night, drinking heavily and randomly phoning people he knew. Between 11:00 pm–2:00 am, Nixon made forty calls, with Kissinger receiving eight of the calls. The Cambodian "incursion" saw American and South Vietnamese troops take the areas of eastern Cambodia that American commanders called the Fish Hook and Parrot's Beak and capture an impressive haul of arms originating from China and the Soviet Union. However, the majority of Vietnamese Communist forces had withdrawn deeper into Cambodia before the invasion, with only a small number left behind to wage a fighting retreat to avoid charges of cowardice.
==== Wound healing ==== Clients who are cleaned by blue tang benefit after suffering an injury. Blue tangs incur many minor injuries, but infection as a result of injuries rarely leads to death. Recovery rates from both minor and major injuries are very high in blue tangs. Injured blue tangs are found to spend more time in cleaning stations compared to those further along in the healing process. This indicates that cleaning plays an important role in the wound healing process. Cleaners pick at the wound and eat the dead tissue in the peripheral area.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.